Table of Contents

Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates and Forecast Timeline
1.3 Research Methodology
1.4 Information Procurement
1.4.1 Purchased database
1.4.2 GVR’s internal database
1.4.3 Secondary sources
1.4.4 Primary research
1.4.5 Details of primary research
1.5 Information or Data Analysis
1.5.1 Data analysis models
1.6 Market Formulation & Validation
1.7 Model Details
1.7.1 Commodity flow analysis
1.7.1.1 Approach 1: Commodity flow approach
1.7.1.2 Approach 2: Country wise market estimation using bottom up approach
1.8 Global Market: CAGR Calculation
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.10.1 Objective 1:
1.10.2 Objective 2:
1.12 List of Tables
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Market Variables, Trends & Scope
3.1 Regulatory and Reimbursement Framework
3.2 Market Variable Analysis
3.2.1 Increasing incidence of cancer
3.2.2 Rising prevalence of metabolic disorders
3.2.3 Presence of strong product pipeline
3.2.4 Technological advancement
3.3 Market Restraint Analysis
3.3.1 Increasing complexity of peptides
3.3.2 High cost of manufacturing equipment
3.4 Penetration and Growth Prospect Mapping
3.5 Peptide Therapeutics Market Analysis Tools
3.5.1 Porter’s five forces analysis
3.5.2 SWOT analysis; by factor (Political & Legal, Economic and Technological)
3.5.3 Major deals & strategic alliances analysis
3.5.3.1 New product launch
3.5.3.2 Mergers and acquisitions
3.5.3.3 Expansion
3.5.3.4 Partnerships
3.5.3.5 Marketing & promotions
3.5.3.6 Market entry strategies
Chapter 4 Application Movement Analysis
4.1 Peptide Therapeutics Market: Application Movement Analysis
4.2 Cancer
4.2.1 Cancer market estimates and forecast, 2018 – 2030 (USD Billion)
4.3 Metabolic Disorders
4.3.1 Metabolic disorders market estimates and forecast, 2018 – 2030 (USD Billion)
4.4 Cardiovascular Disorders
4.4.1 Cardiovascular disorders market estimates and forecast, 2018 – 2030 (USD Billion)
4.5 Dermatological Disorders
4.5.1 Dermatological disorders market estimates and forecast, 2018 – 2030 (USD Billion)
4.6 Infectious Diseases
4.6.1 Infectious diseases market estimates and forecast, 2018 – 2030 (USD Billion)
4.7 Neurological Disorders
4.7.1 Neurological disorders market estimates and forecast, 2018 – 2030 (USD Billion)
4.8 Gastrointestinal Disorders
4.8.1 Gastrointestinal disorders market estimates and forecast, 2018 – 2030 (USD Billion)
4.9 Renal Disorders
4.9.1 Renal disorders market estimates and forecast, 2018 – 2030 (USD Billion)
4.10 Respiratory Disorders
4.10.1 Respiratory disorders market estimates and forecast, 2018 – 2030 (USD Billion)
4.11 Pain
4.11.1 Pain market estimates and forecast, 2018 – 2030 (USD Billion)
4.12 Others
4.12.1 Others market estimates and forecast, 2018 – 2030 (USD Billion)
Chapter 5 Type Movement Analysis
5.1 Peptide therapeutics Market: Type Movement Analysis
5.2 Generic
5.2.1 Generic market estimates and forecast, 2018 – 2030 (USD Billion)
5.3 Innovative
5.3.1 Innovative market estimates and forecast, 2018 – 2030 (USD Billion)
Chapter 6 Type of Manufacturers Movement Analysis
6.1 Peptide Therapeutics Market: Type of Manufacturers Movement Analysis
6.2 In-house
6.2.1 In-house market estimates and forecast, 2018 – 2030 (USD Billion)
6.3 Outsourced
6.3.1 Outsourced market estimates and forecast, 2018 – 2030 (USD Billion)
Chapter 7 Route of Administration Movement Analysis
7.1 Peptide Therapeutics Market: Route of Administration Movement Analysis
7.2 Parenteral
7.2.1 Parenteral market estimates and forecast, 2018 – 2030 (USD Billion)
7.3 Oral
7.3.1 Oral market estimates and forecast, 2018 – 2030 (USD Billion)
7.4 Pulmonary
7.4.1 Pulmonary market estimates and forecast, 2018 – 2030 (USD Billion)
7.5 Mucosal
7.5.1 Mucosal market estimates and forecast, 2018 – 2030 (USD Billion)
7.6 Others
7.6.1 Others market estimates and forecast, 2018 – 2030 (USD Billion)
Chapter 8 Synthesis Technology Movement Analysis
8.1 Peptide Therapeutics Market: Synthesis Technology Movement Analysis
8.2 Solid Phase Peptide Synthesis (SPPS)
8.2.1 SPPS market estimates and forecast, 2018 – 2030 (USD Billion)
8.3 Liquid Phase Peptide Synthesis (LPPS)
8.3.1 LPPS market estimates and forecast, 2018 – 2030 (USD Billion)
8.4 Hybrid
8.4.1 Hybrid market estimates and forecast, 2018 – 2030 (USD Billion)
Chapter 9 Regional Business Analysis
9.1 Peptide Therapeutics Market: Regional Outlook
9.2 North America
9.2.1 North America Peptide Therapeutics Market Estimates And Forecasts, 2018 – 2030 (USD Billion)
9.2.2 U.S.
9.2.2.1 Key Country Dynamics
9.2.2.2 U.S. Peptide Therapeutics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Billion)
9.2.2.3 Target Disease Prevalence
9.2.2.5 Competitive Scenario
9.2.2.6 Regulatory Framework
9.2.2.7 Reimbursement Scenario
9.2.3 Canada
9.2.3.1 Key Country Dynamics
9.2.3.2 Canada Peptide Therapeutics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Billion)
9.2.3.3 Target Disease Prevalence
9.2.3.4 Competitive Scenario
9.2.3.5 Regulatory Framework
9.2.3.6 Reimbursement Scenario
9.3 Europe
9.3.1 Europe Peptide Therapeutics Market Estimates And Forecasts, 2018 – 2030 (USD Billion)
9.3.2 U.K.
9.3.2.1 Key Country Dynamics
9.3.2.2 U.K. Peptide Therapeutics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Billion)
9.3.2.3 Target Disease Prevalence
9.3.2.4 Competitive Scenario
9.3.2.5 Regulatory Framework
9.3.2.6 Reimbursement Scenario
9.3.3 Germany
9.3.3.1 Key Country Dynamics
9.3.3.2 Germany Peptide Therapeutics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Billion)
9.3.3.3 Target Disease Prevalence
9.3.3.4 Competitive Scenario
9.3.3.5 Regulatory Framework
9.3.3.6 Reimbursement Scenario
9.3.4 France
9.3.4.1 Key Country Dynamics
9.3.4.2 France Peptide Therapeutics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Billion)
9.3.4.3 Target Disease Prevalence
9.3.4.4 Competitive Scenario
9.3.4.5 Regulatory Framework
9.3.4.6 Reimbursement Scenario
9.3.5 Italy
9.3.5.1 Key Country Dynamics
9.3.5.2 Italy Peptide Therapeutics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Billion)
9.3.5.3 Target Disease Prevalence
9.3.5.4 Competitive Scenario
9.3.5.5 Regulatory Framework
9.3.5.6 Reimbursement Scenario
9.3.6 Spain
9.3.6.1 Key Country Dynamics
9.3.6.2 Spain Peptide Therapeutics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Billion)
9.3.6.3 Target Disease Prevalence
9.3.6.4 Competitive Scenario
9.3.6.5 Regulatory Framework
9.3.6.6 Reimbursement Scenario
9.3.7 Denmark
9.3.9.1 Key Country Dynamics
9.3.9.2 Denmark Peptide Therapeutics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Billion)
9.3.9.3 Target Disease Prevalence
9.3.9.4 Competitive Scenario
9.3.9.5 Regulatory Framework
9.3.9.6 Reimbursement Scenario
9.3.8 Sweden
9.3.8.1 Key Country Dynamics
9.3.8.2 Sweden Peptide Therapeutics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Billion)
9.3.8.3 Target Disease Prevalence
9.3.8.4 Competitive Scenario
9.3.8.5 Regulatory Framework
9.3.8.6 Reimbursement Scenario
9.3.9 Norway
9.3.9.1 Key Country Dynamics
9.3.9.2 Norway Peptide Therapeutics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Billion)
9.3.9.3 Target Disease Prevalence
9.3.9.4 Competitive Scenario
9.3.9.5 Regulatory Framework
9.3.9.6 Reimbursement Scenario
9.4 Asia Pacific
9.4.1 Asia Pacific Peptide Therapeutics Market Estimates And Forecasts, 2018 – 2030 (USD Billion)
9.4.2 Japan
9.4.2.1 Key Country Dynamics
9.4.2.2 Japan Peptide Therapeutics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Billion)
9.4.2.3 Target Disease Prevalence
9.4.2.4 Competitive Scenario
9.4.2.5 Regulatory Framework
9.4.2.6 Reimbursement Scenario
9.4.3 China
9.4.3.1 Key Country Dynamics
9.4.3.2 China Peptide Therapeutics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Billion)
9.4.3.3 Target Disease Prevalence
9.4.3.4 Competitive Scenario
9.4.3.5 Regulatory Framework
9.4.3.6 Reimbursement Scenario
9.4.4 India
9.4.4.1 Key Country Dynamics
9.4.4.2 India Peptide Therapeutics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Billion)
9.4.4.3 Target Disease Prevalence
9.4.4.4 Competitive Scenario
9.4.4.5 Regulatory Framework
9.4.4.6 Reimbursement Scenario
9.4.5 Australia
9.4.5.1 Key Country Dynamics
9.4.5.2 Australia Peptide Therapeutics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Billion)
9.4.5.3 Target Disease Prevalence
9.4.5.4 Competitive Scenario
9.4.5.5 Regulatory Framework
9.4.5.6 Reimbursement Scenario
9.4.6 South Korea
9.4.6.1 Key Country Dynamics
9.4.6.2 South Korea Peptide Therapeutics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Billion)
9.4.6.3 Target Disease Prevalence
9.4.6.4 Competitive Scenario
9.4.6.5 Regulatory Framework
9.4.6.6 Reimbursement Scenario
9.4.7 Thailand
9.4.7.1 Key Country Dynamics
9.4.7.2 Thailand Peptide Therapeutics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Billion)
9.4.7.3 Target Disease Prevalence
9.4.7.4 Competitive Scenario
9.4.7.5 Regulatory Framework
9.4.7.6 Reimbursement Scenario
9.5 Latin America
9.5.1 Latin America Peptide Therapeutics Market Estimates And Forecasts, 2018 – 2030 (USD Billion)
9.5.2 Brazil
9.5.2.1 Key Country Dynamics
9.5.2.2 Brazil Peptide Therapeutics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Billion)
9.5.2.3 Target Disease Prevalence
9.5.2.4 Competitive Scenario
9.5.2.5 Regulatory Framework
9.5.2.6 Reimbursement Scenario
9.5.3 Mexico
9.5.3.1 Key Country Dynamics
9.5.3.2 Mexico Peptide Therapeutics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Billion)
9.5.3.3 Target Disease Prevalence
9.5.3.4 Competitive Scenario
9.5.3.5 Regulatory Framework
9.5.3.6 Reimbursement Scenario
9.5.4 Argentina
9.5.4.1 Key Country Dynamics
9.5.4.2 Argentina Peptide Therapeutics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Billion)
9.5.4.3 Target Disease Prevalence
9.5.4.4 Competitive Scenario
9.5.4.5 Regulatory Framework
9.5.4.6 Reimbursement Scenario
9.5.4 Chile
9.5.5.1 Key Country Dynamics
9.5.5.2 Chile Peptide Therapeutics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Billion)
9.5.5.3 Target Disease Prevalence
9.5.5.4 Competitive Scenario
9.5.5.5 Regulatory Framework
9.5.5.6 Reimbursement Scenario
9.6 Middle East and Africa
9.6.1 Middle East and Africa Peptide Therapeutics Market Estimates And Forecasts, 2018 – 2030 (USD Billion)
9.6.1.1 Target Disease Prevalence
9.6.1.2 Competitive Scenario
9.6.1.3 Regulatory Framework
9.6.1.4 Reimbursement Scenario
9.6.2 South Africa
9.6.2.1 Key Country Dynamics
9.6.2.2 South Africa Peptide Therapeutics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Billion)
9.6.2.3 Target Disease Prevalence
9.6.2.4 Competitive Scenario
9.6.2.5 Regulatory Framework
9.6.2.6 Reimbursement Scenario
9.6.3 Saudi Arabia
9.6.3.1 Key Country Dynamics
9.6.3.2 Saudi Arabia Peptide Therapeutics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Billion)
9.6.3.3 Target Disease Prevalence
9.6.3.4 Competitive Scenario
9.6.3.5 Regulatory Framework
9.6.3.6 Reimbursement Scenario
9.6.4 UAE
9.6.4.1 Key Country Dynamics
9.6.4.2 UAE Peptide Therapeutics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Billion)
9.6.4.3 Target Disease Prevalence
9.6.4.4 Competitive Scenario
9.6.4.5 Regulatory Framework
9.6.4.6 Reimbursement Scenario
9.6.5 Kuwait
9.6.5.1 Key Country Dynamics
9.6.5.2 Kuwait Peptide Therapeutics Market Estimates & Forecasts And Trend Analysis, 2018 – 2030 (USD Billion)
9.6.5.3 Target Disease Prevalence
9.6.5.4 Competitive Scenario
9.6.5.5 Regulatory Framework
9.6.5.6 Reimbursement Scenario
Chapter 10 Competitive Landscape
10.1 Company Categorization
10.2 Strategy Mapping
10.2.1 New Product Launch
10.2.2 Partnerships
10.2.3 Acquisition
10.2.4 Collaboration
10.2.5 Funding
10.3 Key Company Market Share Analysis, 2022
10.4 Company Profiles
10.4.1 Eli Lilly and Company
10.4.1.1 Company Overview
10.4.1.2 Financial Performance
10.4.1.3 Product Benchmarking
10.4.1.4 Strategic Initiatives
10.4.2 Pfizer, Inc.
10.4.2.1 Company Overview
10.4.2.2 Financial Performance
10.4.2.3 Product Benchmarking
10.4.2.4 Strategic Initiatives
10.4.3 Amgen, Inc.
10.4.3.1 Company Overview
10.4.3.2 Financial Performance
10.4.3.3 Product Benchmarking
10.4.3.4 Strategic Initiatives
10.4.4 Takeda Pharmaceutical Company Limited
10.4.4.1 Company Overview
10.4.4.2 Financial Performance
10.4.4.3 Product Benchmarking
10.4.4.4 Strategic Initiatives
10.4.5 AstraZeneca
10.4.5.1 Company Overview
10.4.5.2 Financial Performance
10.4.5.3 Product Benchmarking
10.4.5.4 Strategic Initiatives
10.4.6 Teva Pharmaceutical Industries Ltd.
10.4.6.1 Company Overview
10.4.6.2 Financial Performance
10.4.6.3 Product Benchmarking
10.4.6.4 Strategic Initiatives
10.4.7 Sanofi
10.4.7.1 Company Overview
10.4.7.2 Financial Performance
10.4.7.3 Product Benchmarking
10.4.7.4 Strategic Initiatives
10.4.8 F. Hoffmann-La Roche Ltd
10.4.8.1 Company Overview
10.4.8.2 Financial Performance
10.4.8.3 Product Benchmarking
10.4.8.4 Strategic Initiatives
10.4.9 Novartis AG
10.4.9.1 Company Overview
10.4.9.2 Financial Performance
10.4.9.3 Product Benchmarking
10.4.9.4 Strategic Initiatives
10.4.10 Novo Nordisk A/S
10.4.10.1 Company Overview
10.4.10.2 Financial Performance
10.4.10.3 Product Benchmarking
10.4.10.4 Strategic Initiatives
10.4.11 GSK plc
10.4.11.1 Company Overview
10.4.11.2 Financial Performance
10.4.11.3 Product Benchmarking
10.4.11.4 Strategic Initiatives
10.4.12 Ironwood Pharmaceuticals, Inc.
10.4.12.1 Company Overview
10.4.12.2 Financial Performance
10.4.12.3 Product Benchmarking
10.4.12.4 Strategic Initiatives
10.4.13 Radius Health, Inc.
10.4.13.1 Company Overview
10.4.13.2 Financial Performance
10.4.13.3 Product Benchmarking
10.4.13.4 Strategic Initiatives
10.4.14 Ipsen Pharma
10.4.14.1 Company Overview
10.4.14.2 Financial Performance
10.4.14.3 Product Benchmarking
10.4.14.4 Strategic Initiatives